Hypokalemia is a vexing problem in end-stage renal disease patients on peritoneal dialysis (PD), and oral potassium supplements (OPS) have limited palatability. Potassium-sparing diuretics (KSD) (spironolactone, amiloride) may be effective in these patients.
Methods
We performed a cross-sectional review of 75 current or past (vintage > 6 months) PD patients with regard to serum potassium (K+), OPS, and KSD utilization. We reviewed charts for multiple clinical and laboratory variables, including dialysis adequacy, residual renal function, nutritional status and co-existing medical therapy.
Results
The cohort was middle-aged with a mean age of 49.2 years (standard deviation [SD] = 14.7) and overweight with a body mass index of 29.5 (6.7) kg/m2. Of all the participants, 57.3% were female, 73.3% African-American, and 48% diabetic with an overall PD vintage of 28.2 (24.3) months at the time of enrollment. Weekly Kt/V was 2.12 (0.43), creatinine clearance was 73.5 (33.6) L/week/1.73 m2 with total daily exchange volume of 10.8 (2.7) L. Residual urine output (RUO) measured at 440 (494) mL (anuric 30.6%). Three-month averaged serum K+ measured at 4 (0.5) mmol/L with 36% of the participants receiving K+ supplements (median: 20 [0;20] mmol/day) and 41.3% KSD (spironolactone dose: 25 – 200 mg/day; amiloride dose: 5 – 10 mg/day). Serum K+ correlated positively with weekly Kt/V (r = 0.239; p = 0.039), PD vintage (r = 0.272; p = 0.018) but not with PD modality, daily exchange volume, RUO, or KSD use. However, KSD use was associated with decreased use of OPS (r = -0.646; p < 0.0001).
Conclusions
Potassium-sparing diuretics were effective in this cohort of PD patients and decreased the need for OPS utilization.
SzetoC.C., ChowK.M., KwanB.C.H., LeungC.B., ChungK.Y., LawM.C.Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication.Am J Kidney Dis2005; 46(1): 128–35.
2.
TorlénK., Kalantar-ZadehK., MolnarM.Z., VashisthaT., MehrotraR.Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort.Clin J Am Soc Nephrol2012; 7(8): 1272–84.
3.
MannJ., YiQ., SleightP., DagenaisG., GersteinH., LonnE.Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.Clin Nephrol2005; 63(3): 181–7.
4.
TzamaloukasA., AvasthiP.S.Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis.Am J Nephrol1987; 7(2): 101–9.
5.
YongsiriS., ThammakumpeeJ., ProngnamchaiS., TengpraettanakornP., ChueansuwanR., TangjaturonrasmeS.Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients.Ther Apher Dial2015; 19(1): 81–6.
GóesC.R., BerbelM.N., BalbiA.L., PonceD.Approach to the metabolic implications of peritoneal dialysis in acute kidney injury.Perit Dial Int2015; 35(4): 397–405.
8.
RibeiroS.C., FigueiredoA.E., BarrettiP., Pecoits-FilhoR., de MoraesT.P.Low serum potassium levels increase the infectious-caused mortality in peritoneal dialysis patients: a propensity-matched score study.PLOS ONE2015; 10(6): e0127453.
NewmanL., WeissM., BergerJ., PriesterA., NegreaL., CachoC.The law of unintended consequences in action: increase in incidence of hypokalemia with improved adequacy of dialysis.Adv Perit Dial1999; 16: 134–7.
AndrewM.E., JonesD.W., WoffordM.R., WyattS.B., SchreinerP.J., BrownC.A.Ethnicity and unprovoked hypokalemia in the Atherosclerosis Risk in Communities Study.Am J Hypertens2002; 15(7): 594–9.
13.
KantA.K., GraubardB.I., KumanyikaS.K.Trends in black-white differentials in dietary intakes of US adults, 1971–2002.Am J Prev Med2007; 32(4): 264–72.
14.
McCaaR.E., McCaaC.S., BowerJ.D., GuytonA.C.Increased plasma aldosterone concentration in response to hemodialysis in nephrectomized man.Circ Res1972; 31(4): 473–80.
15.
ZabetakisP., KumarD., GleimG., GardenswartzM., AgrawalM., RobinsonA.Increased levels of plasma renin, aldosterone, catecholamines and vasopressin in chronic ambulatory peritoneal dialysis (CAPD) patients.Clin Nephrol1987; 28(3): 147–51.
16.
DrechslerC., RitzE., TomaschitzA., PilzS., SchönfeldS., BlouinK.Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients.Eur Heart J2013; 34(8): 578–87.
17.
MarkP.B., TaylorA.H., McQuarrieE.P., JardineA.G.How is the heart best protected in chronic dialysis patients?Sem Dialysis2014; 27(4): 328–32.
18.
CovicA., Gusbeth-TatomirP., GoldsmithD.J.Is it time for spironolactone therapy in dialysis patients?Nephrol Dial Transplant2006; 21(4): 854–8.
19.
PoesenR., MeijersB., EvenepoelP.The colon: an overlooked site for therapeutics in dialysis patients.Sem Dialysis2013; 26(3): 323–32.
20.
LiddleG.W.Aldosterone antagonists and triamterene.Ann NY Acad Sci1966; 139(2): 466–70.
SiscovickD.S., RaghunathanT., PsatyB.M., KoepsellT.D., WicklundK.G., LinX.Diuretic therapy for hypertension and the risk of primary cardiac arrest.N Engl J Med1994; 330(26): 1852–7.
23.
SaudanP., MachF., PernegerT., SchnetzlerB., StoermannC., FumeauxZ.Safety of low-dose spironolactone administration in chronic haemodialysis patients.Nephrol Dial Transplant2003; 18(11): 2359–63.
24.
NiX., ZhangJ., ZhangP., WuF., XiaM., YingG.Effects of spironolactone on dialysis patients with refractory hyper tension: a randomized controlled study.J Clin Hypertens2014; 16(9): 658–63.
25.
MatsumotoY., MoriY., KageyamaS., AriharaK., SugiyamaT., OhmuraH.Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.J Am Coll Cardiol2014; 63(6): 528–36.
26.
GrossE., RothsteinM., DombekS., JuknisH.I.Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.Am J Kidney Dis2005; 46(1): 94–101.
27.
WangA.Y.M., BrimbleK.S., BrunierG., HoltS.G., JhaV., JohnsonD.W.ISPD cardiovascular and metabolic guidelines in adult peritoneal dialysis patients part I–assessment and management of various cardiovascular risk factors.Perit Dial Int2015; 35(4): 379–87.
28.
ZsomL., ZsomM., FülöpT., WellsC., FlessnerM.F., EllerJ.Correlation of treatment time and ultrafiltration rate with serum albumin and C-reactive protein levels in patients with end-stage kidney disease receiving chronic maintenance hemodialysis: a cross-sectional study.Blood purif2010; 30(1): 8–15.
29.
ChuangY.W., ShuK.H., YuT.M., ChengC.H., ChenC.H.Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients.Nephrol Dial Transplant2009; 24(5): 1603–8.
30.
KimH.W., ChangJ.H., ParkS.Y., MoonS.J., KimD.K., LeeJ.E.Factors associated with hypokalemia in continuous ambulatory peritoneal dialysis patients.Electrolyte Blood Press2007; 5(2): 102–10.
31.
DimitriadisC., SekerciogluN., PipiliC., OreopoulosD., BargmanJ.M.Hyponatremia in peritoneal dialysis: epidemiology in a single center and correlation with clinical and biochemical parameters.Perit Dial Int2014; 34(3): 260–70.
32.
ZannadF., KesslerM., LehertP., GrünfeldJ., ThuilliezC., LeizoroviczA.Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.Kidney Int2006; 70(7): 1318–24.
33.
LinC., ZhangQ., ZhangH., LinA.Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study.J Clin Hypertens2016; 18(2): 121–8.
34.
YelkenB., GorguluN., GursuM., YaziciH., CaliskanY., TelciA.Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients.Adv Perit Dial2014; 30: 5–10.
35.
ErsoyR., CelikA., YilmazO., SariogluS., SisB., AkanP.The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats.Perit Dial Int2007; 27(4): 424–31.
36.
NessimS.J., PerlJ., BargmanJ.M.The renin–angiotensin–aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?Kidney Int2010; 78(1): 23–8.
37.
KwokJ.S.S., ChowK.M., KwanB.C.H., LiP.K.T., SzetoC.C.Spironolactone is not effective for the treatment of hypokalemia in peritoneal dialysis patients.Hong Kong J Nephrol2007; 9(1): 36–40.
38.
TaheriS., MortazaviM., PourmoghadasA., SeyrafianS., AlipourZ., KarimiS.A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.Saudi J Kidney Dis Transpl2012; 23(3): 507–12.
39.
ItoY., MizunoM., SuzukiY., TamaiH., HiramatsuT., OhashiH.Long-term effects of spironolactone in peritoneal dialysis patients.J Am Soc Nephrol2013; 25(5): 1094–102.
40.
SpitalA., SternsR.H.Potassium supplementation via the dialysate in continuous ambulatory peritoneal dialysis.Am J Kidney Dis1985; 6(3): 173–6.
41.
TziviskouE., MussoC., BellizziV., KhandelwalM., WangT., SavajS.Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature.Int Urol Nephrol2003; 35(3): 429–34.
42.
SchmidtD.S., SalahudeenA.K.Cardiovascular and survival pradoxes in dialysis patients: obesity-survival paradox—still a controversy?Sem Dialysis2007; 20(6): 486–92.
43.
WilsonD., Metcalfe-GibsonA., WrongO.The chemical composition of faeces in uraemia, as revealed by in-vivo faecal dialysis.Clin Sci1968; 35(2): 197–209.
44.
TapolyaiM.B., FaludiM., BertaK., SzarvasT., LengvárszkyZ., MolnarM.Z.The effect of ambient temperature and humidity on inter-dialytic weight gains in end-stage renal disease patients.Int Urol Nephrol2016; [E-pub ahead of print.]
